Content Type: Commentary & Opinion

Accelerated Approval and Expensive Drugs—A Challenging Combination

March 16, 2026

Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry

March 16, 2026

Real-World Evidence And Regulatory Drug Approval

March 16, 2026

Who Is Now Responsible for Discovering and Warning About Adverse Effects of Generic Drugs?

March 16, 2026

Paying Patients for Their Tissue: The Legacy of Henrietta Lacks

March 16, 2026

Value-Based Pricing of Drugs with Multiple Indications or in Combinations—Lessons From Europe

March 16, 2026

Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug Availability

March 16, 2026

Ensuring Access to Injectable Generic Drugs—The Case of Intravesical BCG for Bladder Cancer

March 16, 2026

The Shortage of Normal Saline in the Wake of Hurricane Maria

March 16, 2026

Using a Drug-Safety Tool to Prevent Competition

March 16, 2026

Strategies to Improve the Affordability of Insulin in the USA

March 16, 2026

The Promise of ESCAT: A New System for Evaluating Cancer Drug-Target Pairs

March 16, 2026